Skip to main content

Table 1 Profile of background factors by temperature increase and oximetry decrease 24-h post-infusion of sotrovimab and the area under curve (AUC) of the receiver operating characteristic analysis for the outcome of fever and/or dyspnea

From: Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events

Factor

Division (Unit)

Total

Receiver operating characteristics analysis

N = 139

Median (Inter-quartile range)

AUC

95% CI, Lower

95% CI, Upper

P value

Sex

Male

73

    

0.999

Female

66

     

Smoking

Yes

65

    

0.627

Never

74

     

2 or 3-Dose

Vaccination

Yes

119

    

0.687

No

20

     

Age

(Years)

 

69.0 (54.0–85.0)

0.49

0.385

0.595

0.831

Body Mass Index

(kg/m2)

 

22.4 (19.9–25.9)

0.425

0.313

0.537

0.017

Symptomatic

(Day)

 

2.0 (1.0–3.0)

0.399

0.301

0.497

0.022

PreTemp

Celsius

 

36.7 (36.2–37.0)

0.765

0.679

0.852

 < 0.001

PreOx

(%)

 

97.0 (96.0–98.0)

0.36

0.251

0.468

0.002

While Blood Cell

(× 103)

 

5.05 (4.04–6.02)

0.585

0.472

0.698

0.172

Neutrophil

(%)

 

62.6 (53.5–70.7)

0.693

0.594

0.791

0.007

Lymphocytes

(%)

 

23.9 (19.0–32.5)

0.287

0.195

0.38

0.001

C-reactive protein

(mg/dl)

 

1.11 (0.36–2.59)

0.603

0.501

0.706

0.136

Total Bilirubin

(mg/dl)

 

0.50 (0.40–0.70)

0.532

0.426

0.638

0.699

Creatinine

(mg/dl)

 

0.84 (0.68–1.11)

0.619

0.512

0.726

0.145

Platelet

(× 103)

 

182.0 (143.3–224.8)

0.392

0.288

0.497

0.077

  1. PreTemp, pre-infusion body temperature more than 36.7 degrees Celsius; PreOx, pre-infusion pulse oximetry below 94%; CI, confidence interval